Lymphocyte Drug Sensitivity Is Useful for Prediction of the Antiproteinuric Effect and Relapse Rate in Cyclosporine Treatment for Frequent-Relapse Minimal Change Nephrotic Syndrome

Abstract

Background/Aims: The therapeutic effect of cyclosporine A (CsA) in combination with steroids varies greatly for frequent-relapse minimal change nephrotic syndrome (FRMCNS). The association between the sensitivity of peripheral blood lymphocytes (PBLs) to CsA in vitro and the therapeutic effect of CsA in FRMCNS were investigated. Methods: The sensitivity of PBLs in vitro and the therapeutic effect of CsA in 23 FRMCNS patients were compared. The length of time to complete remission (CR) and the number of relapses were compared using the 50% inhibitory concentration (IC₅₀) of CsA in the presence of a T-cell mitogen. Results: FRMCNS patients were divided into 2 groups: a low sensitivity group with an IC₅₀ of >14.8 ng/ml (GII, n = 10), and a high sensitivity group with an IC₅₀ of <14.8 ng/ml (GI, n = 13). Comparison of the length of time to CR between the 2 groups showed that GI reached CR earlier than GII (p < 0.01). GI had significantly fewer relapses than GII when CsA was administered for 12 months or longer (p < 0.01). Conclusion: Lymphocyte sensitivity to CsA has the potential to be an important clinical indicator of the antiproteinuric effect and relapse rate in FRMCNS.

Journal

Journal ID (publisher-id): KBR

Journal ID (nlm-ta): Kidney Blood Press Res

Journal ID (doi): 10.1159/issn.1420-4096

Title: Kidney and Blood Pressure Research

Publisher: S. Karger AG

ISSN (Print): 1420-4096

ISSN (Electronic): 1423-0143

Publication date Subscription-year: 2005

Publication date (Print): December 2005

Publication date (Electronic): 27 December 2005

Volume: 28

Issue: 4

Pages: 226-229

Affiliations

^aRenal Unit, Department of Internal Medicine, Hachioji Medical Center, Tokyo Medical University, and ^bDepartment of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan

Article

Publisher ID: 87768 Other ID: Kidney Blood Press Res 2005;28:226–229

DOI: 10.1159/000087768

PubMed ID: 16118505

Copyright statement: © 2005 S. Karger AG, Basel

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Page count

Figures: 1, Tables: 3, References: 6, Pages: 4

Product

Self URI (application/pdf): https://www.karger.com/Article/Pdf/87768

Self URI (text/html): https://www.karger.com/Article/FullText/87768

Self URI (journal page): https://www.karger.com/SubjectArea/Nephrology

Categories

Subject: Rapid Communication